Cargando…

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevations in total cholesterol (TC) and low density lipoprotein cholesterol (LDLc). Development of FH can result in the increase of risk for premature cardiovascular diseases (CVD). FH is primarily caused by genet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lye, Say-Hean, Chahil, Jagdish Kaur, Bagali, Pramod, Alex, Livy, Vadivelu, Jamunarani, Ahmad, Wan Azman Wan, Chan, Siew-Pheng, Thong, Meow-Keong, Zain, Shamsul Mohd, Mohamed, Rosmawati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620484/ https://www.ncbi.nlm.nih.gov/pubmed/23593297 http://dx.doi.org/10.1371/journal.pone.0060729

Ejemplares similares

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes
por: Derenbecker, Robert, et al.
Publicado: (2019)

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia
por: Lv, Xian, et al.
Publicado: (2023)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells
por: Nawaka, Nantiya, et al.
Publicado: (2022)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
por: Ma, Shizhan, et al.
Publicado: (2019)

Uptake of (68)gallium in atherosclerotic plaques in LDLR(-/-)ApoB(100/100 )mice
por: Silvola, Johanna MU, et al.
Publicado: (2011)

Role of genetic & environment risk factors in the aetiology of colorectal cancer in Malaysia
por: Ramzi, Nurul Hanis, et al.
Publicado: (2014)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Chlamydia pneumoniae Infection Exacerbates Atherosclerosis in ApoB100only/LDLR(−/−) Mouse Strain
por: Lantos, Ildikó, et al.
Publicado: (2018)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

ApoB100/LDLR-/- Hypercholesterolaemic Mice as a Model for Mild Cognitive Impairment and Neuronal Damage
por: Ramírez, Carlos, et al.
Publicado: (2011)

Western Diet Decreases Hepatic Drug Metabolism in Male LDLr(−/−)ApoB(100/100) Mice
por: Koponen, Markus, et al.
Publicado: (2023)

Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

LDLR gene’s promoter region hypermethylation in patients with familial hypercholesterolemia
por: Zorzo, R. A., et al.
Publicado: (2023)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Effects of APOE, APOB and LDLR variants on serum lipids and lack of association with xanthelasma in individuals from Southeastern Brazil
por: Nakazone, Marcelo A., et al.
Publicado: (2009)

Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs
por: Davis, Bryan T., et al.
Publicado: (2014)

Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia
por: Kizhakkedath, Praseetha, et al.
Publicado: (2019)

Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways
por: Yuefeng, Yu, et al.
Publicado: (2022)

Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia
por: Thomas, Ellen R A, et al.
Publicado: (2013)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants
por: Benito-Vicente, Asier, et al.
Publicado: (2018)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia
por: Goldmann, Radan, et al.
Publicado: (2010)

A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene
por: Nagahara, Keiko, et al.
Publicado: (2019)

Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model
por: Li, Zhelong, et al.
Publicado: (2021)

Mucosal Tolerance to a Combination of ApoB and HSP60 Peptides Controls Plaque Progression and Stabilizes Vulnerable Plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J Mice
por: Mundkur, Lakshmi, et al.
Publicado: (2013)

Hepatic S1P deficiency lowers plasma cholesterol levels in apoB-containing lipoproteins when LDLR function is compromised
por: Basu, Debapriya, et al.
Publicado: (2015)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_havvbvl2jq55gha3gd29e1jh1l